ArticleClinical ophthalmology (Auckland, N.Z.)2018
A novel system, TearCare
Article in Clinical ophthalmology (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03006978 (A Prospective, Single-center, Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in Adults With Dry Eye Disease TearCare Pilot Study)), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Single-center, Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare System in Adults With Dry Eye Disease TearCare Pilot Study)
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Durability of the TearCare treatment effect in subjects with dry eye disease: Stage 3 of the Sahara randomized controlled trial.Optometry and vision science : official publication of the American Academy of Optometry · 2025Trial
- Improved Signs and Symptoms of Dry Eye Disease for RestasisClinical ophthalmology (Auckland, N.Z.) · 2024Trial
- TheraPearl Eye Mask and Blephasteam for the treatment of meibomian gland dysfunction: a randomized, comparative clinical trial.Scientific reports · 2021Trial
- A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCareClinical ophthalmology (Auckland, N.Z.) · 2020Trial
- Technological Interventions for Dry Eye Disease: A Systematic Review and Random-Effects Network Meta-analysis of 3-Month Outcomes.Ophthalmology and therapy · 2026Article
- Dry Eye Disease Management Via Technological Methods: A Systematic Review and Network Meta-analysis.Ophthalmology and therapy · 2025Article
- Quintessence of currently approved and upcoming treatments for dry eye disease.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Review
- Comparison of manual versus automated thermal lid therapy with expression for meibomian gland dysfunction in patients with dry eye disease.Scientific reports · 2024Article
- Meibomian Gland Dysfunction Clinical Practice Guidelines.Japanese journal of ophthalmology · 2023Article
- Meibomian gland dysfunction patients benefit in ocular parameters and tear chemokines after thermal pulsation treatment.International journal of medical sciences · 2023Article
- Dry eye syndrome: comprehensive etiologies and recent clinical trials.International ophthalmology · 2022Review
- Eyelid Warming Devices: Safety, Efficacy, and Place in Therapy.Clinical optometry · 2022Review
- A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Alternative therapies for dry eye disease.Current opinion in ophthalmology · 2021Review
- Therapeutic Instruments Targeting Meibomian Gland Dysfunction.Ophthalmology and therapy · 2020Review
- The negative effects of dry eye disease on quality of life and visual functionTurkish journal of medical sciences · 2020Review
- Infrared thermography: different options of thermal eyelid warming.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Article
- Advances in dry eye disease treatment.Current opinion in ophthalmology · 2019Review
- TearCareClinical ophthalmology (Auckland, N.Z.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe objective of this study was to evaluate the safety and effectiveness of the TearCare PATIENTS AND
methodsThis was a prospective, single-center, randomized, parallel-group, clinical trial. Subjects with DED were randomized to either a single TearCare treatment conducted at the clinic or 4 weeks of daily warm compress (WC) therapy. The TearCare procedure consisted of 12 minutes of thermal eyelid treatment immediately followed by manual expression of the meibomian glands. WC therapy consisted of once daily application of the compresses to the eyelids for 5 minutes. Subjects were followed until 6 months post-treatment. The primary effectiveness end point was defined as change from baseline to 4 weeks for tear breakup time (TBUT). Secondary effectiveness end points included meibomian gland assessment, corneal and conjunctival staining scores, and assessment of dry eye symptoms using validated questionnaires. Safety was evaluated by collecting device-related adverse events, intraocular pressure, and best spectacle-corrected Snellen Visual acuity.
resultsTwenty-four subjects were enrolled and all subjects completed 6 months follow-up. At the 1-month follow-up, TearCare subjects demonstrated an improvement from baseline in mean (±SD) TBUT of 11.7±2.6 seconds compared with an average worsening of -0.3±1.1 seconds for subjects in the WC group (
conclusionThe findings of this pilot study suggest that the TearCare System is an effective treatment option for patients with DED, with the effects on the signs and symptoms of DED persisting for at least 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.